Digital Weight-Loss Prescriptions Spur Medical and Regulatory Scrutiny
Online weight-loss prescriptions issued through rapid digital consultations frequently bypass thorough medical evaluations, creating severe health risks for vulnerable patients, according to a Yale University study published in the journal JAMA. Researchers examining 49 United States websites offering weight-loss medications found that 92 percent of the platforms issued prescriptions using a fictional patient profile. Only 55 percent of the sites asked about prior eating disorders, and just a third required a telephone or video consultation with healthcare personnel. Prescriptions were issued within 24 hours on average, with two cases taking approximately five minutes.
The findings have raised urgent concerns among eating disorder specialists and medical regulators regarding digital prescribing practices for glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatid. While these medications represent major advancements in obesity treatment, specialists warn they can exacerbate severe undernutrition and reinforce harmful behaviors in patients struggling with anorexia. CNN interviewed several individuals affected by these practices, including 40-year-old AJ Jasper from Chicago, who received GLP-1 medications by mail after completing a brief online questionnaire with false weight information. Jasper, who has lived with anorexia for much of his life, never spoke with a physician via video call, and the resulting treatment deterioration led to January hospitalization for organ failure.
Corporate Defenses and Ongoing Research Into Eating Disorders
Telehealth providers maintain that robust screening protocols are built into their digital intake systems. The U.S. telehealth company Hims & Hers stated that inquiries regarding eating disorders are a mandatory component of its prescription workflow, designed to trigger secondary medical reviews and specialist referrals when flagged. Other digital care providers report similar safeguard mechanisms to identify high-risk patients. Meanwhile, manufacturers Novo Nordisk and Eli Lilly emphasize that their products lack regulatory approval for treating eating disorders, with Eli Lilly stressing that independent digital providers bear sole responsibility for their medical evaluations.
Concurrently, researchers are investigating whether GLP-1 medications might offer therapeutic value for other eating disorders, such as binge eating disorder. Preliminary results, such as this study, suggest potential benefits, though experts caution that unmonitored digital access remains dangerous.
Regulatory Investigations and Legislative Response in Sweden
While the initial study focused on the American market, regulatory and journalistic reviews in Sweden have uncovered parallel vulnerabilities in online prescribing habits. During the fall of 2024, the Swedish television program SVT Assignment Review investigated nine online clinics and found that six prescribed Ozempic or Wegovy to a reporter who did not meet clinical treatment criteria. Erik Galli, a reporter with a history of eating disorders who participated in the broadcast, described a resurgence of destructive thoughts surrounding food and weight after starting Ozempic.
Regulatory scrutiny has intensified in response to these findings. In February 2025, the Health and Social Care Inspectorate (The Inspectorate for Health and Social Care, or IVO) issued formal criticism against the digital clinic Yazen, citing specific concerns regarding patient self-reporting of weight and inadequate medical assessments. Following government initiatives, a state inquiry presented proposals in March 2026 to grant IVO expanded supervisory powers and improve authority access to prescription records. The consultation period for these legislative proposals closed on September 28, though new laws have not yet been enacted. Additionally, the Swedish government commissioned the National Board of Health and Welfare (National Board of Health and Welfare) to map obesity drug prescriptions and evaluate discrepancies among various healthcare providers.
Frequently Asked Questions About Online GLP-1 Prescriptions
What specific criteria did the Yale study use to test online weight-loss sites?
Researchers used a fictional patient profile to test 49 American websites offering weight-loss drugs to evaluate the strictness of required medical evaluations before a prescription was issued.
How quickly do online platforms typically issue weight-loss prescriptions?
Prescriptions are issued within 24 hours on average, with certain digital platforms approving requests in approximately five minutes based solely on questionnaire responses.
What regulatory changes are currently under discussion in Sweden?
A state inquiry presented in March 2026 proposes giving IVO expanded oversight capabilities and better authority to audit prescription data, following a consultation period that ended on September 28.
Which Swedish authority criticized the digital clinic Yazen and when?
IVO issued formal criticism against Yazen in February 2025, pointing to risks associated with patient self-reported weight data and insufficient clinical evaluations.
Worth a look